NASDAQ:PBYIPuma Biotechnology Stock Price, Forecast & News

Puma Biotechnology's stock was trading at $9.27 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PBYI shares have increased by 14.2% and is now trading at $10.59. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 3 sell ratings, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Puma Biotechnology.

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Puma Biotechnology.

Puma Biotechnology Inc (NASDAQ:PBYI) issued its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.77) by $0.34. The biopharmaceutical company had revenue of $51.20 million for the quarter, compared to analysts' expectations of $44.42 million. Puma Biotechnology had a negative return on equity of 500.98% and a negative net margin of 36.72%. The business's revenue was down 48.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.21 earnings per share. View Puma Biotechnology's earnings history.

10 analysts have issued twelve-month price targets for Puma Biotechnology's shares. Their forecasts range from $6.00 to $17.00. On average, they anticipate Puma Biotechnology's share price to reach $12.63 in the next twelve months. This suggests a possible upside of 19.2% from the stock's current price. View analysts' price targets for Puma Biotechnology.

News coverage about PBYI stock has been trending negative this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Puma Biotechnology earned a news impact score of -2.8 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutPuma Biotechnology.

Puma Biotechnology saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 7,870,000 shares, a decline of 6.8% from the April 30th total of 8,440,000 shares. Based on an average trading volume of 1,360,000 shares, the days-to-cover ratio is currently 5.8 days. Approximately 23.2% of the shares of the stock are sold short. View Puma Biotechnology's Current Options Chain.

Some companies that are related to Puma Biotechnology include Heron Therapeutics (HRTX), Opko Health (OPK), Zogenix (ZGNX), Dicerna Pharmaceuticals (DRNA), Theravance Biopharma (TBPH), Ironwood Pharmaceuticals (IRWD), Akcea Therapeutics (AKCA), CytoDyn (CYDY), BELLUS Health (BLUSF), Y-mAbs Therapeutics (YMAB), Constellation Pharmaceuticals (CNST), Amneal Pharmaceuticals (AMRX), Arcus Biosciences (RCUS), ZEALAND PHARMA/S (ZEAL) and I-Mab (IMAB). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Kite Pharma (KITE), Array Biopharma (ARRY), Freeport-McMoRan (FCX) and Celgene (CELG).

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Puma Biotechnology's stock is owned by many different institutional and retail investors. Top institutional investors include State Street Corp (8.99%), BlackRock Inc. (7.16%), Fred Alger Management LLC (5.93%), Camber Capital Management LP (4.95%), Federated Hermes Inc. (2.56%) and Acadian Asset Management LLC (2.22%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Charles R Eyler, Douglas M Hunt and Richard Paul Bryce. View institutional ownership trends for Puma Biotechnology.

PBYI stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Ikarian Capital LLC, WINTON GROUP Ltd, Deutsche Bank AG, Rafferty Asset Management LLC, Parametric Portfolio Associates LLC, Two Sigma Advisers LP, and Jane Street Group LLC. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Douglas M Hunt, and Richard Paul Bryce. View insider buying and selling activity for Puma Biotechnology.

PBYI stock was purchased by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Sofinnova Investments Inc., Fred Alger Management LLC, Tang Capital Management LLC, Federated Hermes Inc., UBS Group AG, Trexquant Investment LP, and Thrivent Financial for Lutherans. View insider buying and selling activity for Puma Biotechnology.

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PBYI stock can currently be purchased for approximately $10.59.

Puma Biotechnology has a market capitalization of $416.86 million and generates $272.30 million in revenue each year. The biopharmaceutical company earns $-75,600,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Puma Biotechnology employs 272 workers across the globe.

The official website for Puma Biotechnology is www.pumabiotechnology.com.

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]